Rosuvastatin tablets
Reason category: Dissolution failure
FDA recall number D-0292-2026
Cholesterol (statin)
Rosuvastatin 10 mg tablet
Public data on rosuvastatin from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
$0.0355
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-43%
change over five years
peak $7.0736 in 2016-07
29
approved generic applications (ANDAs) on record for Rosuvastatin Calcium
19 with a product still marketed · first 2016
Not listed
in FDA's current shortage list
no matching FDA shortage entries
NADAC per unit, monthly
ROSUVASTATIN CALCIUM 10 MG TABShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2016-07 | 7.07359 |
| 2016-10 | 0.39674 |
| 2017-01 | 0.26853 |
| 2017-04 | 0.20235 |
| 2017-07 | 0.15860 |
| 2017-10 | 0.13871 |
| 2018-01 | 0.12818 |
| 2018-04 | 0.11699 |
| 2018-07 | 0.10918 |
| 2018-10 | 0.11268 |
| 2019-01 | 0.10071 |
| 2019-04 | 0.10029 |
| 2019-07 | 0.10126 |
| 2019-10 | 0.10224 |
| 2020-01 | 0.10042 |
| 2020-04 | 0.09601 |
| 2020-07 | 0.08358 |
| 2020-10 | 0.06926 |
| 2021-01 | 0.07170 |
| 2021-04 | 0.07166 |
| 2021-07 | 0.06380 |
| 2021-10 | 0.06410 |
| 2022-01 | 0.06143 |
| 2022-04 | 0.05982 |
| 2022-07 | 0.05279 |
| 2022-10 | 0.05411 |
| 2023-01 | 0.05180 |
| 2023-04 | 0.05112 |
| 2023-07 | 0.05306 |
| 2023-10 | 0.05124 |
| 2024-01 | 0.05068 |
| 2024-04 | 0.04575 |
| 2024-07 | 0.03846 |
| 2024-10 | 0.04583 |
| 2025-01 | 0.03956 |
| 2025-04 | 0.04246 |
| 2025-07 | 0.04204 |
| 2025-10 | 0.04023 |
| 2026-01 | 0.03964 |
| 2026-04 | 0.03777 |
| 2026-07 | 0.03834 |
| 2026-10 | 0.03578 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning rosuvastatin
openFDA enforcement records, by year reported.
| 2026 | 1 |
| 2025 | 1 |
| 2023 | 10 |
| 2014 | 1 |
13 records since 2012. A record is one product or lot, not one recall event. Combination products that contain rosuvastatin are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Rosuvastatin calcium tablets
Reason category: cGMP deviations
FDA recall number D-0339-2025
Rosuvastatin product
Reason category: cGMP deviations
FDA recall number D-0495-2023
Rosuvastatin product
Reason category: cGMP deviations
FDA recall number D-0501-2023
Rosuvastatin product
Reason category: cGMP deviations
FDA recall number D-0500-2023
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention rosuvastatin
16 GxRadar articles cite or discuss this drug.
Price histories · Data story · 6 min
How fast generic prices fell for rosuvastatin, duloxetine and tadalafil
Federal cost data show three widely used generics each fell more than 90 percent within 24 months of entry. One did it in five weeks. Month-by-month figures, lined up against FDA approval dates.
Market economics · Explainer · 5 min
What happens to Medicaid spending when the first generic arrives
Federal research on prices after generic entry, and four worked examples from NADAC and Medicaid claims data: duloxetine, valsartan, rosuvastatin and tadalafil.
FDA programs · Data story · 5 min
What FDA's yearly first generics lists show
FDA's 2025 first generics list has 91 entries, but one entry is not one medicine and approval is not launch. What the lists count, and what price data show after a first copy arrives.
Market economics · Explainer · 5 min
Why generic prices fall as competitors enter
One generic maker cuts the brand price by about 39 percent; six or more cut it by over 95 percent. FDA's 2019 study, GAO data and GxRadar's NADAC files show how steep the curve is and why.
Price histories · Data story · 6 min
What pharmacies paid for simvastatin, 2013 to 2026
Federal survey data put a generic 20 mg simvastatin tablet at 2.7 cents in November 2013 and 3.2 cents in October 2026. The year-by-year record, the 2023 jump and the approvals behind the market.
Price histories · Data story · 5 min
What pharmacies paid for atorvastatin, 2013 to 2026
Federal survey data show the pharmacy cost of a generic 20 mg atorvastatin tablet fell from 18.3 cents in November 2013 to 2.8 cents in October 2026. The year-by-year record, and the FDA approvals behind it.